中国P站

Gynecologic Cancer; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; Immunotherapy; Targeted Therapy; Precision Medicine; PARP Inhibitors; Biomarkers; Human Papillomavirus (HPV); Uterine Leiomyosarcoma

Introduction

This review highlights significant advancements in ovarian cancer therapy, moving beyond traditional surgery and chemotherapy to include novel strategies. It emphasizes the growing role of molecularly targeted agents, particularly PARP inhibitors, and the emerging potential of immunotherapy[1].

This review offers a comprehensive look at the role of immunotherapy in cervical cancer, particularly in advanced and recurrent settings. It details the efficacy of checkpoint inhibitors, both as monotherapy and in combination with chemotherapy or radiation, highlighting their ability to overcome treatment resistance[2].

This article delves into the molecular classification of endometrial cancer, a critical advance in understanding tumor heterogeneity and guiding treatment strategies. It details the four main molecular subgroups—POLE ultramutated, MSI hypermutated, p53 abnormal, and no specific molecular profile (NSMP)—and explains how these classifications predict prognosis and inform therapeutic choices[3].

This review provides an overview of the evolving landscape of targeted therapies across various gynecologic malignancies, including ovarian, cervical, and endometrial cancers. It discusses the mechanisms of action for various small molecule inhibitors and monoclonal antibodies that target specific signaling pathways critical for tumor growth and survival[4].

This review explores the evolving paradigm of precision medicine in ovarian cancer treatment, emphasizing the tailoring of therapies based on molecular profiles and genetic alterations. It discusses the integration of genomics, transcriptomics, and proteomics to identify actionable targets and predict treatment response, particularly for PARP inhibitors and other targeted agents[5].

This review outlines the evolution and future prospects of cervical cancer screening, emphasizing the shift towards Human Papillomavirus (HPV)-based primary screening methods. It discusses the advantages of HPV testing over cytology in terms of sensitivity and objectivity, along with strategies for optimal triage of HPV-positive women[6].

This article reviews the burgeoning role of immunotherapy in endometrial cancer, particularly focusing on checkpoint inhibitors and their efficacy in different molecular subtypes. It highlights how the presence of microsatellite instability (MSI-H) and high tumor mutational burden (TMB-H) predicts a favorable response to immune checkpoint blockade[7].

This systematic review provides an updated perspective on the diagnostic and therapeutic management of vulvar cancer, focusing on squamous cell carcinoma, the most common histological type. It discusses the evolving role of surgical approaches, including sentinel lymph node biopsy, to minimize morbidity while maintaining oncologic safety[8].

This article addresses the critical need for effective early detection biomarkers in ovarian cancer, given its often late-stage diagnosis and poor prognosis. It evaluates the current utility and limitations of established markers like CA-125 and reviews promising novel candidates, including circulating tumor DNA (ctDNA), microRNAs, and proteomic signatures[9].

This review examines the latest developments in the treatment of uterine Leiomyosarcoma (ULMS), a rare and aggressive gynecologic malignancy. It covers the challenges in diagnosis and the importance of accurate pathological assessment. The article discusses advancements in surgical techniques, the limited role of conventional chemotherapy, and explores emerging systemic therapies, including targeted agents and immunotherapies[10].

Description

Recent innovations are significantly advancing ovarian cancer therapy, moving beyond traditional surgery and chemotherapy to embrace novel strategies. This includes a growing focus on molecularly targeted agents, like PARP inhibitors, and the emerging potential of immunotherapy. Precision medicine plays a key role, tailoring treatments based on individual tumor characteristics to improve patient outcomes and extend progression-free survival [1, 5]. The broader landscape of gynecologic malignancies, encompassing ovarian, cervical, and endometrial cancers, also sees the evolution of targeted therapies. These involve small molecule inhibitors and monoclonal antibodies that specifically target signaling pathways essential for tumor growth and survival, despite challenges of resistance, with combination strategies showing promise [4]. This individualized approach is reshaping clinical trials and offering more effective, less toxic treatment options for patients with diverse tumor characteristics [5].

Immunotherapy has a prominent role in cervical cancer, especially in advanced and recurrent cases. Checkpoint inhibitors demonstrate efficacy both as monotherapy and when combined with chemotherapy or radiation, helping overcome treatment resistance. Emerging immunotherapeutic strategies, such as therapeutic vaccines and adoptive cell therapy, point towards personalized approaches for better patient management [2]. Similarly, for endometrial cancer, immunotherapy is burgeoning, with a focus on checkpoint inhibitors and their effectiveness across different molecular subtypes. The presence of microsatellite instability (MSI-H) and a high tumor mutational burden (TMB-H) are key predictors for a favorable response to immune checkpoint blockade. Ongoing clinical trials explore novel combinations and adoptive cell therapies, marking a promising shift in the therapeutic landscape for advanced or recurrent endometrial disease [7].

Molecular classification is a critical advance for endometrial cancer, providing insight into tumor heterogeneity and guiding treatment. Four main molecular subgroups are recognized: POLE ultramutated, MSI hypermutated, p53 abnormal, and no specific molecular profile (NSMP). These classifications predict prognosis and inform therapeutic choices, including the use of targeted agents and immunotherapy, underscoring the importance of integrating molecular testing into routine clinical practice for improved patient stratification [3]. Beyond classification, the critical need for effective early detection biomarkers in ovarian cancer is a major focus, given its often late-stage diagnosis and poor prognosis. Researchers are evaluating the utility of established markers like CA-125 and investigating promising novel candidates such as circulating tumor DNA (ctDNA), microRNAs, and proteomic signatures. Developing highly sensitive and specific biomarkers is challenging, but multi-marker panels and Artificial Intelligence (AI) hold potential for improving diagnostic accuracy and facilitating early intervention [9].

Cervical cancer screening is undergoing a significant evolution, emphasizing the shift towards Human Papillomavirus (HPV)-based primary screening methods. HPV testing offers advantages over cytology in sensitivity and objectivity, and strategies for optimal triage of HPV-positive women are improving. The potential of self-sampling and novel biomarker development is also being explored to enhance accessibility and accuracy, supporting global efforts for improved early detection and prevention [6]. Meanwhile, the diagnostic and therapeutic management of rarer gynecologic malignancies continues to advance. For vulvar cancer, particularly squamous cell carcinoma, surgical approaches like sentinel lymph node biopsy are evolving to minimize morbidity while maintaining oncologic safety. Advancements in radiotherapy and chemotherapy, coupled with risk stratification, are leading to personalized treatment plans aimed at improving recurrence rates and overall survival [8]. Uterine Leiomyosarcoma (ULMS), an aggressive and rare gynecologic malignancy, presents unique diagnostic challenges, but emerging systemic therapies, including targeted agents and immunotherapies, offer new hope for better patient prognoses [10].

Conclusion

Significant progress is reshaping gynecologic cancer treatment, shifting from traditional approaches to precision medicine and novel therapies. Ovarian cancer now benefits from molecularly targeted agents, notably PARP inhibitors, and emerging immunotherapies, leading to improved patient outcomes and extended progression-free survival [1, 5]. Immunotherapy also plays a critical role in advanced and recurrent cervical cancer, utilizing checkpoint inhibitors and exploring therapeutic vaccines and adoptive cell therapy to overcome resistance [2]. Endometrial cancer treatment is advanced by molecular classification, which informs therapeutic decisions including targeted agents and immunotherapy based on specific tumor profiles like POLE ultramutated or MSI hypermutated subtypes [3, 7]. Targeted therapies generally are evolving across various gynecologic malignancies, employing small molecule inhibitors and monoclonal antibodies to target crucial signaling pathways, with ongoing research into combination strategies [4]. Early detection remains a priority, particularly for ovarian cancer, where research focuses on improving biomarkers beyond CA-125, incorporating circulating tumor DNA and proteomic signatures, and leveraging Artificial Intelligence (AI) for enhanced diagnostic accuracy [9]. Cervical cancer screening is moving towards Human Papillomavirus (HPV)-based methods, improving sensitivity and accessibility through innovations like self-sampling [6]. Furthermore, advances in managing rarer cancers, such as vulvar cancer, involve refined surgical techniques and personalized treatment plans [8], while uterine Leiomyosarcoma (ULMS) sees hope in emerging systemic targeted agents and immunotherapies [10].

References

• Xinning Z, Xiaoying X, Ruihua W (2024) .Gynecol Oncol 181:169-178.

, ,

• Claudia PM, Marisa RN, Carlos CG (2023) .Gynecol Oncol Res Pract 10:22.

, ,

• Xiaoli H, Zhicheng L, Yanhua D (2022) .Cancers (Basel) 14:1727.

, ,

• Yu-Fei T, Ru-Yi C, Yu-Ying D (2023) .Signal Transduct Target Ther 8:63.

, ,

• Matteo S, Giovanni S, Sara BC (2021) .Cancers (Basel) 13:4848.

, ,

• Marianna DZ, Marco Z, Matteo C (2021) .Cancers (Basel) 13:6056.

, ,

• Francesca LM, Claudia LC, Valentina LDS (2022) .Cancers (Basel) 14:1661.

, ,

• Ilaria DL, Claudia C, Alessandro D (2020) .Oncol Ther 8:11-25.

, ,

• Antonella C, Giovanni BSC, Martina SF (2023) .J Clin Med 12:1697.

, ,

• Xiaohui W, Mengmeng X, Jihui J (2022) .Front Oncol 12:955427.

, ,